美国伊利诺伊州多站点医疗系统耳念珠菌感染治疗临床结局
Candida auris is an emerging fungal pathogen that is typically resistant to fluconazole and is known to cause healthcare-associated outbreaks. We retrospectively reviewed 28 patients who had >1 positive culture for C.…
要点
- 耳念珠菌感染患者临床结局较好,83%住院治疗患者达到临床成功。
- 多数患者经验性使用米卡芬净治疗。
- 分离株对氟康唑耐药率为14%,对两性霉素B和棘白菌素耐药率均为3.6%。
核心结论
- 耳念珠菌感染患者抗真菌耐药率较低,多数患者临床结局良好。
研究设计与样本
- 回顾性研究,纳入美国伊利诺伊州多站点医疗系统2018年5月至2019年4月28例耳念珠菌培养阳性患者。
主要发现
- 28例分离株中,4株(14%)对氟康唑耐药,1株(3.6%)对两性霉素B耐药,1株(3.6%)对棘白菌素耐药。
关键数值与推荐
- 临床成功定义为首次阳性培养后30天内无全因死亡、无耳念珠菌复发、无感染相关再入院。
- 92%的患者经验性接受米卡芬净治疗。
临床怎么用
- 对于耳念珠菌感染,可考虑经验性使用米卡芬净,但需注意当地耐药情况。
局限性
- 回顾性研究,样本量较小(28例),仅来自单一医疗系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Candida auris is an emerging fungal pathogen that is typically resistant to fluconazole and is known to cause healthcare-associated outbreaks. We retrospectively reviewed 28 patients who had >1 positive culture for C. auris within a multisite health system in Illinois, USA, during May 2018-April 2019. Twelve of these patients were treated as inpatients for C. auris infections; 10 (83%) met criteria for clinical success, defined as absence of all-cause mortality, C. auris recurrence, and infection-related readmission at 30 days from the first positive culture. The other 2 patients (17%) died within 30 days. Most patients (92%) were empirically treated with micafungin. Four (14%) of 28 total isolates were resistant to fluconazole, 1 (3.6%) was resistant to amphotericin B, and 1 (3.6%) was resistant to echinocandins. Our findings describe low rates of antifungal resistance and favorable clinical outcomes for most C. auris patients.
引用
- Arensman K, Miller JL, Chiang A, et al. Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System, Illinois, USA. Emerg Infect Dis. 2020. PMID: 32310077. doi:10.3201/eid2605.191588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。